$RVMD News
Last published 1w ago
- 1w agoRVMDRevolution Medicines, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoRVMDRevolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswireReceived U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent
- 2w agoRVMDRevolution Medicines to Participate in November 2026 Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines
- 2w agoRVMDRevolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026GlobeNewswireExpanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with
- 3w agoRVMDRevolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026GlobeNewswireREDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines
- 3w agoRVMDRevolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung CancerGlobeNewswireREDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines
- 3w agoRVMDRevolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic CancerGlobeNewswireRecommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and
- 4w agoEXELGMABONCYRVMD+1Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with
- 1mo agoONCYRVMDAMGNLLY+1KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireEquity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the...
- 1mo agoRVMDRevolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic CancerGlobeNewswireCompany receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for
- 2mo agoRVMDNew England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerGlobeNewswireResults support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines,
- 2mo agoRVMDU.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic CancerGlobeNewswireRASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapyIn the
- 2mo agoRVMDApproval of Rasonque, Nda #220910 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 08/26/2026; Drug Name: Rasonque, Nda #220910; Active Ingredients: DARAXONRASIB; Company: Revolution Medicines Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 220910
- 3mo agoONCRVMDBeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization CollaborationBusiness WireClinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne
- 3mo agoRVMDRevolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswireU.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 resultsRapidly implemented U.S. Expanded Access Program for
- 3mo agoRVMDRevolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026GlobeNewswireREDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 3mo agoRVMDRevolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic CancerGlobeNewswireREDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 4mo agoLLYRVMDAMGNPFEReed Jobs would rather talk about curing cancer than his last nameTechCrunch
- 4mo agoRVMDEuropean Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review ProcessGlobeNewswirePhased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial Rolling
- 4mo agoRVMDRevolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026GlobeNewswireREDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 4mo agoRVMDRevolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026GlobeNewswireREDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral
- 4mo agoRVMDRevolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic CancerGlobeNewswireREDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has
- 4mo agoRVMDRevolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.GlobeNewswireSteve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy
- 5mo agoCYDYMRNAOTLCRVMD+1Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 BillionGlobeNewswireAUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are
- 5mo agoRVMDRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic CancerGlobeNewswireREDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 5mo agoRVMDRevolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO PresentationGlobeNewswireREDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 6mo agoRVMDRevolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerGlobeNewswireREDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that The New
- 6mo agoRVMDRevolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswireDaraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute
- 6mo agoRVMDRevolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026GlobeNewswireREDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 6mo agoAXPAMZNGSATWMT+9BitsStifel Insights
- 6mo agoRVMDRevolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual MeetingGlobeNewswireREDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 6mo agoRVMDRevolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual MeetingGlobeNewswireREDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 6mo agoRVMDRevolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual MeetingGlobeNewswireREDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 6mo agoRVMDRevolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual MeetingGlobeNewswireREDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 6mo agoRVMDRevolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireREDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 7mo agoRVMDRevolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewswireREDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of
- 7mo agoRVMDRevolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior NotesGlobeNewswireREDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its intention
- 7mo agoRVMDRevolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trialCNBCRevolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial.
- 7mo agoRVMDDaraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic CancerGlobeNewswireTrial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug
- 7mo agoRVMDFormer Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancerCNBCFormer Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic cancer.
- 7mo agoRVMDRevolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic CancerGlobeNewswireREDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has
- 8mo agoRVMDRevolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressGlobeNewswireOn track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three
- 8mo agoRVMDRevolution Medicines to Participate in TD Cowen 46th Annual Health Care ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 8mo agoRVMDRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026GlobeNewswireREDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 9mo agoRVMDRevolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026GlobeNewswireREDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 9mo agoRVMDRevolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective InhibitorGlobeNewswireREDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first
- 10mo agoRVMDRevolution Medicines Announces FDA Breakthrough Therapy Designation for ZoldonrasibGlobeNewswireBreakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with
- 10mo agoRVMDRevolution Medicines to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
- 10mo agoRVMDRevolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant ChemotherapyGlobeNewswireREDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first
- 1y agoRVMDRevolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate ProgressGlobeNewswireCompany is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute